SCHEMBL623187

SCHEMBL623187

CC(C)COc1cc(N2CCN(C(=O)CNC(=O)c3cccc4[nH]ccc34)CC2)ncn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.39
POLB P06746 1/20 0.39
ATM Q13315 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PDGFRB P09619 1/20 0.38
LRRK2 Q5S007 3/20 0.37
P2RY12 Q9H244 2/20 0.36
KDM4E B2RXH2 2/20 0.36
F2 P00734 1/20 0.36
CHRM2 P08172 1/20 0.36
HDAC1 Q13547 2/20 0.35
HDAC2 Q92769 2/20 0.35
MAPK14 Q16539 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623275 0.87 MAPK14 (0.48) PDGFRBLRRK2CHRM2MAPK14GOT1
SCHEMBL622758 0.85 KDM4E (0.44) TP53HSD17B10PDGFRBLRRK2KDM4E
SCHEMBL15006743 0.81 KMT2A (0.50) POLBATMP2RY12KDM4EKMT2A
SCHEMBL624480 0.81 P2RY12 (0.44) TP53POLBATMHSD17B10P2RY12
SCHEMBL12473598 0.79 LRRK2 (0.38) LRRK2P2RY12KDM4EKMT2ACYP2C19
SCHEMBL624486 0.78 THRA (0.45) POLBP2RY12KDM4EKMT2ARAB9A
SCHEMBL624206 0.76 NPC1 (0.45) TP53POLBATMHSD17B10KDM4E
SCHEMBL624097 0.76 LMNA (0.45) HSD17B10KDM4EHDAC1HDAC2HDAC3
SCHEMBL624147 0.74 MAPK14 (0.48) KDM4EMAPK14GOT1RAB9ASMN1; SMN2
SCHEMBL623147 0.73 ALDH1A1 (0.52) LRRK2KMT2ANPSR1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G TP53 4837/4885POLB 3044/4885ATM 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.